U.S. Markets closed

Biocon Limited (BIOCON.NS)


NSE - NSE Real Time Price. Currency in INR
Add to watchlist
892.70-53.65 (-5.67%)
At close: 3:30PM IST
Interactive chart
Previous Close946.35
Open946.35
Bid0.00 x
Ask0.00 x
Day's Range886.90 - 946.50
52 Week Range642.45 - 1,188.00
Volume1,746,888
Avg. Volume774,959
Market Cap175.13B
BetaN/A
PE Ratio (TTM)28.82
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters28 days ago

    India watchdog orders antitrust probe into Roche cancer drug

    India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients. Trastuzumab has been a mainstay of Roche's profit for years and brought in global sales of about $6.7 billion in 2016, but it has been challenged in the last three years by biosimilars which are sold at about a 25 percent discount to the original. India's Biocon and U.S. firm Mylan, which together sell biosimilars of the drug in over a dozen countries including India, filed a complaint with the Competition Commission of India (CCI) last year alleging Roche misled doctors and regulators to thwart competition to trastuzumab.

  • Mylan's Proposed Biosimailar for Cancer Under Review in U.S.
    Zacks3 months ago

    Mylan's Proposed Biosimailar for Cancer Under Review in U.S.

    Mylan N.V. (MYL) and Biocon Ltd. announced that the FDA has accepted their biologics license application for a biosimilar version of Amgen's (AMGN) Neulasta (pegfilgrastim) - MYL-1401H.

  • Mylan/Biocon's Herceptin Biosimilar under Review in the U.S.
    Zacks4 months ago

    Mylan/Biocon's Herceptin Biosimilar under Review in the U.S.

    Mylan (MYL) and Biocon Ltd. announced that the FDA had accepted the BLA for their biosimilar version of Herceptin (trastuzumab), MYL-1401O.